The FSA Spy market buzz – 26 April 2024
Golden mystery, Next big Healthtech thing, Plastic everywhere, The Magnificent Seven wane, Dreary fund presentation hell, Putting The Economist in its place, A touch of Shakespeare and much more.
FE Fundinfo, which bases its assessment on a fund’s three-year history of delivering alpha, minimising relative volatility and producing consistent returns, assigns a top five-crown rating to the GQG fund, but has not rated the FSSA product – perhaps because of its short history.
Morningstar has awarded the GQG fund five stars, and a silver forward-looking analyst rating. The FSSA is awarded three stars by Morningstar.
“Both are reasonably concentrated funds investing in quality companies,” said McDermott.
“On paper, the GQG fund is stronger. But both products have a strong process and are currently overweight India, underweight China and have good spread of other emerging market holdings which I agree with,” he said.
“The FSSA fund may appeal to those who want a more responsible investment. Although it is not an ESG fund, the company itself has strong ESG principles and has been investing on the right side of the debate for a number of years.”
“I think the FSSA fund is worth monitoring, but for now the GQG fund gets my vote,” McDermott concluded.
Golden mystery, Next big Healthtech thing, Plastic everywhere, The Magnificent Seven wane, Dreary fund presentation hell, Putting The Economist in its place, A touch of Shakespeare and much more.
Part of the Mark Allen Group.